COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.

Miklos GulyasJohanna Sofia Margareta MattssonAndrea LindgrenLars EkKristina Lamberg LundströmAnnelie BehndigErik Carl Viktor HolmbergPatrick MickeBengt Bergmannull null

Published in: Acta oncologica (Stockholm, Sweden) (2017)

In this subgroup analysis of patients with advanced NSCLC treated within the context of a randomized trial, we could not detect any interaction effect of COX-2 expression in tumor or stromal cells and the outcome of celecoxib treatment in addition to standard chemotherapy.

Keyphrases

advanced non small cell lung cancer
poor prognosis
epidermal growth factor receptor
locally advanced
small cell lung cancer
binding protein
long non coding rna
open label